361 related articles for article (PubMed ID: 8053580)
1. Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model.
Gentry WB; Krejcie TC; Henthorn TK; Shanks CA; Howard KA; Gupta DK; Avram MJ
Anesthesiology; 1994 Aug; 81(2):316-24; discussion 25A. PubMed ID: 8053580
[TBL] [Abstract][Full Text] [Related]
2. Early phase pharmacokinetics but not pharmacodynamics are influenced by propofol infusion rate.
Masui K; Kira M; Kazama T; Hagihira S; Mortier EP; Struys MM
Anesthesiology; 2009 Oct; 111(4):805-17. PubMed ID: 19741485
[TBL] [Abstract][Full Text] [Related]
3. Predictive ability of propofol effect-site concentrations during fast and slow infusion rates.
Sepúlveda PO; Cortínez LI; Recart A; Muñoz HR
Acta Anaesthesiol Scand; 2010 Apr; 54(4):447-52. PubMed ID: 20003124
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental.
Shanks CA; Avram MJ; Krejcie TC; Henthorn TK; Gentry WB
J Pharmacokinet Biopharm; 1993 Jun; 21(3):309-21. PubMed ID: 8258770
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
[TBL] [Abstract][Full Text] [Related]
7. C50 for propofol-remifentanil target-controlled infusion and bispectral index at loss of consciousness and response to painful stimulus in Chinese patients: a multicenter clinical trial.
Xu Z; Liu F; Yue Y; Ye T; Zhang B; Zuo M; Xu M; Hao R; Xu Y; Yang N; Che X
Anesth Analg; 2009 Feb; 108(2):478-83. PubMed ID: 19151275
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
Cox EH; Kuipers JA; Danhof M
Br J Pharmacol; 1998 Aug; 124(7):1534-40. PubMed ID: 9723968
[TBL] [Abstract][Full Text] [Related]
9. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Deschamps C; Dubruc C; Mentre F; Rosenzweig P
Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
[TBL] [Abstract][Full Text] [Related]
11. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam.
Albrecht S; Ihmsen H; Hering W; Geisslinger G; Dingemanse J; Schwilden H; Schüttler J
Clin Pharmacol Ther; 1999 Jun; 65(6):630-9. PubMed ID: 10391668
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
Gupta SK; Granneman GR; Boger RS; Hollenberg NK; Luther RR
Drug Metab Dispos; 1992; 20(6):821-5. PubMed ID: 1362933
[TBL] [Abstract][Full Text] [Related]
14. Influence of administration rate on propofol plasma-effect site equilibration.
Struys MM; Coppens MJ; De Neve N; Mortier EP; Doufas AG; Van Bocxlaer JF; Shafer SL
Anesthesiology; 2007 Sep; 107(3):386-96. PubMed ID: 17721240
[TBL] [Abstract][Full Text] [Related]
15. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules.
Snoeck E; Jacqmin P; Sargentini-Maier ML; Stockis A
Epilepsy Res; 2007 Sep; 76(2-3):140-7. PubMed ID: 17851036
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
Breithaupt-Grögler K; Malerczyk C; Belz GG; Butzer R; Herrmann V; Stass H; Wensing G
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):434-41. PubMed ID: 9352392
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
18. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.
Stanski DR; Maitre PO
Anesthesiology; 1990 Mar; 72(3):412-22. PubMed ID: 2310020
[TBL] [Abstract][Full Text] [Related]
20. The effect of preoperative heart rate and anxiety on the propofol dose required for loss of consciousness.
Gras S; Servin F; Bedairia E; Montravers P; Desmonts JM; Longrois D; Guglielminotti J
Anesth Analg; 2010 Jan; 110(1):89-93. PubMed ID: 19910628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
